Literature DB >> 17311085

Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+ CD3+ count reconstitution is associated with survival.

U Koehl1, K Bochennek, S Y Zimmermann, T Lehrnbecher, J Sörensen, R Esser, C Andreas, C Kramm, H P Grüttner, E Falkenberg, A Orth, P Bader, D Schwabe, T Klingebiel.   

Abstract

To evaluate the correlation between kinetics of immune reconstitution and survival, we prospectively evaluated lymphocyte subsets in 32 paediatric patients undergoing allogeneic stem cell transplantation (SCT) for haematological malignancies. Four-colour flow cytometric analysis was performed at short intervals with a median follow-up of 4 years post SCT. A total of 50% of patients reached age-matched 5th percentile of natural killer, cytotoxic T, B and helper T cells 4, 9, 20 and 28 weeks after SCT, respectively, which increased to more than 80% within 1 year after SCT. Transplantation of peripheral blood stem cells (PBSC) seemed to elicit the fastest reconstitution of CD3+, CD4+ CD3+, CD8+ CD3+ and naïve T cells compared to bone marrow (BM) or CD34-selected PBSC, which did not differ. Most importantly, we observed a significantly higher number of survivors among patients whose CD8+ CD3+ absolute counts rose above the 5th percentile of age-matched normal levels during the first year post SCT compared to patients who never reached these levels (19/25 vs 0/7, P<0.001). This was still present in both subgroups, BM- and CD34-selected grafts (P=0.03, 0.02). These results from a small patient sample underline the importance of particular lymphocyte subsets for the outcome of children undergoing SCT. A larger study with detailed subset analysis is underway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311085     DOI: 10.1038/sj.bmt.1705584

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.

Authors:  Amir A Toor; Roy T Sabo; Harold M Chung; Catherine Roberts; Rose H Manjili; Shiyu Song; David C Williams; Wendy Edmiston; Mandy L Gatesman; Richard W Edwards; Andrea Ferreira-Gonzalez; William B Clark; Michael C Neale; John M McCarty; Masoud H Manjili
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

2.  ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56+CD3- NK cells.

Authors:  U Koehl; K Bochennek; R Esser; A Brinkmann; R Quaritsch; M Becker; J Soerensen; P Bader; D Schwabe; T Klingebiel; J Fischer; S Y Zimmermann
Journal:  Int J Hematol       Date:  2007-12-18       Impact factor: 2.490

Review 3.  Recent advances in hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.

Authors:  Veronica Jude; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

4.  Dendritic cell reconstitution is associated with relapse-free survival and acute GVHD severity in children after allogeneic stem cell transplantation.

Authors:  M C Elze; O Ciocarlie; A Heinze; S Kloess; T Gardlowski; R Esser; T Klingebiel; P Bader; S Huenecke; M Serban; U Köhl; J L Hutton
Journal:  Bone Marrow Transplant       Date:  2014-11-10       Impact factor: 5.483

5.  The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation.

Authors:  Roberta Fedele; Massimo Martino; Cristina Garreffa; Giuseppe Messina; Giuseppe Console; Domenica Princi; Antonella Dattola; Tiziana Moscato; Elisabetta Massara; Elisa Spiniello; Giuseppe Irrera; Pasquale Iacopino
Journal:  Blood Transfus       Date:  2012-01-24       Impact factor: 3.443

6.  Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Ming-Rui Huo; Lan-Ping Xu; Dai-Hong Liu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  J Clin Immunol       Date:  2011-12-16       Impact factor: 8.317

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial).

Authors:  C A Keever-Taylor; J E Wagner; N A Kernan; T N Small; S L Carter; J S Thompson; G A Cloud; L S Lamb
Journal:  Bone Marrow Transplant       Date:  2009-07-20       Impact factor: 5.483

9.  Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts.

Authors:  Xuying Pei; Xiangyu Zhao; Yu Wang; Lanping Xu; Xiaohui Zhang; Kaiyan Liu; Yingjun Chang; Xiaojun Huang
Journal:  Front Med       Date:  2017-09-08       Impact factor: 4.592

10.  Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients.

Authors:  Swati Naik; Spyridoula Vasileiou; Paibel Aguayo-Hiraldo; Shivani Mukhi; Ghadir Sasa; Caridad Martinez; Robert A Krance; Stephen Gottschalk; Ann Leen
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.